Loading
NASDAQHealthcareBiotechnology
Latest quote
$2.98
+$0.09 · +3.11%
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Previous close
$2.98
+$0.09 · +3.11%
Regular session · ET · Market data may be delayed.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Day range
Current $2.98
52-week range
Current $2.98
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
33
Expensive
Sentiment
61
Bullish
Risk
60
Elevated Risk
Momentum
44
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Day range
Current $2.98
52-week range
Current $2.98
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 1.32M USD | 2.24M USD | 23.9M USD | 60.88M USD |
| Cost of goods sold | 3.08M USD | 4.79M USD | 3.75M USD | 3.29M USD | 1.65M USD |
| Gross profit | −3.08M USD | −3.47M USD | −1.51M USD | 20.61M USD | 59.22M USD |
| Research and development | 34.35M USD | 30.16M USD | 16.52M USD | 36.44M USD | 57.18M USD |
| Selling, general, and administrative | 14.6M USD | 9.28M USD | 23.8M USD | 16.38M USD | 17.09M USD |
| Operating expenses | 45.87M USD | 39.44M USD | 36.57M USD | 49.53M USD | 72.62M USD |
| Interest income | 1.43M USD | 1.29M USD | 584.97K USD | 71.07K USD | 23.12K USD |
| Interest expense | 240.66K USD | 318.4K USD | 315.28K USD | 301.58K USD | 294.46K USD |
| Depreciation and amortization | 3.08M USD | 4.79M USD | 3.75M USD | 3.29M USD | 1.65M USD |
| Operating income | −48.95M USD | −42.91M USD | −38.08M USD | −28.92M USD | −13.39M USD |
| Net income | 13.27M USD | −34.11M USD | −42.19M USD | −18.74M USD | −17.15M USD |
Company facts updated Oct 11, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
